INCYTE CORPORATION Equity Securities, FV-NI, Unrealized Gain (Loss)
INCYTE CORPORATION (INCY) reported Equity Securities, FV-NI, Unrealized Gain (Loss) of $99.95 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-04-30.
Discontinued › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss · last filed 2024-04-30
- INCYTE CORPORATION equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2024-03-31 was $99.95M.
- INCYTE CORPORATION equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2023-12-31 was $34.05M.
- INCYTE CORPORATION equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2023-09-30 was -$26.65M.
- INCYTE CORPORATION equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2023-06-30 was $41.81M.
- INCYTE CORPORATION equity securities, fv-ni, unrealized gain (loss) for fiscal 2023 was $43.89M.
- INCYTE CORPORATION equity securities, fv-ni, unrealized gain (loss) for fiscal 2022 was -$87.59M.
- INCYTE CORPORATION equity securities, fv-ni, unrealized gain (loss) for fiscal 2021 was -$24.07M, a 330.88% decline from fiscal 2020.
- INCYTE CORPORATION equity securities, fv-ni, unrealized gain (loss) for fiscal 2020 was $10.43M, a 69.74% decline from fiscal 2019.
| Period end | Equity Securities, FV-NI, Unrealized Gain (Loss) 3 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 6 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 9 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2024-03-31 | $99.95M 10-Q · filed 2024-04-30 | $134.00M derived: sum of 2 quarters · filed 2024-04-30 | $107.35M derived: sum of 3 quarters · filed 2024-04-30 | $149.16M derived: sum of 4 quarters · filed 2024-04-30 |
| 2023-12-31 | $34.05M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-13 | $7.40M derived: sum of 2 quarters · filed 2024-02-13 | $49.21M derived: sum of 3 quarters · filed 2024-02-13 | $43.89M 10-K · filed 2024-02-13 |
| 2023-09-30 | -$26.65M 10-Q · filed 2023-10-31 | $15.16M derived: sum of 2 quarters · filed 2023-10-31 | $9.84M 10-Q · filed 2023-10-31 | -$5.61M derived: sum of 4 quarters · filed 2024-04-30 |
| 2023-06-30 | $41.81M 10-Q · filed 2023-08-01 | $36.49M 10-Q · filed 2023-08-01 | $21.05M derived: sum of 3 quarters · filed 2024-04-30 | $20.39M derived: sum of 4 quarters · filed 2024-04-30 |
| 2023-03-31 | -$5.32M 10-Q · filed 2024-04-30 | -$20.77M derived: sum of 2 quarters · filed 2024-04-30 | -$21.43M derived: sum of 3 quarters · filed 2024-04-30 | -$46.32M derived: sum of 4 quarters · filed 2024-04-30 |
| 2022-12-31 | -$15.45M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-13 | -$16.11M derived: sum of 2 quarters · filed 2024-02-13 | -$41.01M derived: sum of 3 quarters · filed 2024-02-13 | -$87.59M 10-K · filed 2024-02-13 |
| 2022-09-30 | -$660.00K 10-Q · filed 2023-10-31 | -$25.56M derived: sum of 2 quarters · filed 2023-10-31 | -$72.14M 10-Q · filed 2023-10-31 | -$67.82M derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-06-30 | -$24.90M 10-Q · filed 2023-08-01 | -$71.48M 10-Q · filed 2023-08-01 | -$67.16M derived: sum of 3 quarters · filed 2024-02-13 | -$94.61M derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-03-31 | -$46.59M 10-Q · filed 2023-05-02 | -$42.26M derived: sum of 2 quarters · filed 2024-02-13 | -$69.71M derived: sum of 3 quarters · filed 2024-02-13 | -$42.95M derived: sum of 4 quarters · filed 2024-02-13 |
| 2021-12-31 | $4.32M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-13 | -$23.13M derived: sum of 2 quarters · filed 2024-02-13 | $3.64M derived: sum of 3 quarters · filed 2024-02-13 | -$24.07M 10-K · filed 2024-02-13 |
| 2021-09-30 | -$27.45M 10-Q · filed 2022-11-01 | -$685.00K derived: sum of 2 quarters · filed 2022-11-01 | -$28.39M 10-Q · filed 2022-11-01 | -$28.90M derived: sum of 4 quarters · filed 2023-02-07 |
| 2021-06-30 | $26.77M 10-Q · filed 2022-08-02 | -$944.00K 10-Q · filed 2022-08-02 | -$1.45M derived: sum of 3 quarters · filed 2023-02-07 | -$14.66M derived: sum of 4 quarters · filed 2023-02-07 |
| 2021-03-31 | -$27.71M 10-Q · filed 2022-05-03 | -$28.22M derived: sum of 2 quarters · filed 2023-02-07 | -$41.42M derived: sum of 3 quarters · filed 2023-02-07 | $30.85M derived: sum of 4 quarters · filed 2023-02-07 |
| 2020-12-31 | -$509.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-07 | -$13.72M derived: sum of 2 quarters · filed 2023-02-07 | $58.56M derived: sum of 3 quarters · filed 2023-02-07 | $10.43M 10-K · filed 2023-02-07 |
| 2020-09-30 | -$13.21M 10-Q · filed 2021-11-02 | $59.07M derived: sum of 2 quarters · filed 2021-11-02 | $10.94M 10-Q · filed 2021-11-02 | $26.69M derived: sum of 4 quarters · filed 2022-02-08 |
| 2020-06-30 | $72.27M 10-Q · filed 2021-08-03 | $24.14M 10-Q · filed 2021-08-03 | $39.90M derived: sum of 3 quarters · filed 2022-02-08 | $42.24M derived: sum of 4 quarters · filed 2022-02-08 |
| 2020-03-31 | -$48.13M 10-Q · filed 2021-05-04 | -$32.38M derived: sum of 2 quarters · filed 2022-02-08 | -$30.04M derived: sum of 3 quarters · filed 2022-02-08 | -$34.66M derived: sum of 4 quarters · filed 2022-02-08 |
| 2019-12-31 | $15.76M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-08 | $18.09M derived: sum of 2 quarters · filed 2022-02-08 | $13.47M derived: sum of 3 quarters · filed 2022-02-08 | $34.46M 10-K · filed 2022-02-08 |
| 2019-09-30 | $2.34M 10-Q · filed 2020-11-05 | -$2.29M derived: sum of 2 quarters · filed 2020-11-05 | $18.70M 10-Q · filed 2020-11-05 | -$3.48M derived: sum of 4 quarters · filed 2021-02-09 |
| 2019-06-30 | -$4.63M 10-Q · filed 2020-08-04 | $16.36M 10-Q · filed 2020-08-04 | -$5.82M derived: sum of 3 quarters · filed 2021-02-09 | -$15.77M derived: sum of 4 quarters · filed 2021-02-09 |
| 2019-03-31 | $20.99M 10-Q · filed 2020-05-05 | -$1.19M derived: sum of 2 quarters · filed 2021-02-09 | -$11.14M derived: sum of 3 quarters · filed 2021-02-09 | -$45.78M derived: sum of 4 quarters · filed 2021-02-09 |
| 2018-12-31 | -$22.18M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-09 | -$32.13M derived: sum of 2 quarters · filed 2021-02-09 | -$66.77M derived: sum of 3 quarters · filed 2021-02-09 | -$44.09M 10-K · filed 2021-02-09 |
| 2018-09-30 | -$9.95M 10-Q · filed 2019-10-29 | -$44.59M derived: sum of 2 quarters · filed 2019-10-29 | -$21.91M 10-Q · filed 2019-10-29 | |
| 2018-06-30 | -$34.64M 10-Q · filed 2019-07-30 | -$11.96M 10-Q · filed 2019-07-30 | ||
| 2018-03-31 | $22.68M 10-Q · filed 2019-04-30 | |||
| 2017-12-31 | -$24.27M 10-K · filed 2020-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| IQVIA HOLDINGS INC. (IQV) | United States | $45.926B | 20.54 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B |